DTaP or diphtheria and tetanus toxoids and acellular pertussis are a combination of vaccines given to humans in order to protect against the infective diphtheria, tetanus and pertussis disease. Diphtheria causes breathing problems, paralysis and heart failure for individuals, while tetanus can affect individuals that can lead to muscle tightening, jaw locking and swelling. Additionally, the pertussis vaccine (aP) causes excessive coughing making it difficult for infants to swallow, chew and eat. The DTaP vaccines are given to infants either once altogether or in form of four doses given at different stages. Of all these, pertussis is a communicable disease which occurs more prominently among infants. These vaccines are recommended for children, teenagers and pregnant women, in order to boost their immunity against these diseases and are available mostly in combination with hepatitis B and haemophilus influenza type b (Hib) in form of a pentavalent vaccine.
The global diphtheria, tetanus and pertussis vaccine (DTaP) market is anticipated to record a modest CAGR over the forecast period i.e. 2019-2027, owing to increased awareness about the diseases and prevalence of high birth rates. The initiatives taken up by both government and other organizations such as NGOs to provide better child care vaccination is anticipated to increase the growth of the market over the forecast period. Additionally, the increase in accessibility of vaccines globally coupled with increased investment of private sector in healthcare is anticipated to increase the demand for the vaccine over the forecast period. The initiatives by World Health Organization (WHO) and United Nations International Children’s Emergency Fund (UNICEF) have resulted in 9 out of 10 children receiving their first dosage, thereby helping protect most of the children from such infectious diseases. However, significant increase in population and growing child birth rates are anticipated to increase the demand for second dosage, which is expected to contribute to the growth of the market over the forecast period.
The market is segmented into disease type, product type, vaccine type and by end user . The disease type segment is further segmented into diphtheria, tetanus and pertussis, out of which the pertussis segment is anticipated to occupy the leading market share, owing to increased cases of infants affected by pertussis as compared to other segments. The pertussis disease is anticipated to witness around 1, 00,000 cases globally during the forecast period. Additionally, the vaccines are given at the time of pregnancy in order to increase the level of antibodies within infant’s body. The vaccination centers forming part of end user segment is estimated to witness significant growth, on account of increasing number of regular cases that are to be attended to, coupled with availability of vaccines as compared to other segments.
Get more information on this report: Download Sample PDF
The various initiatives taken by WHO and UNICEF to supply low cost vaccines to low income countries globally is anticipated to drive the growth of the market over the forecast period. The governments are taking initiatives globally to promote vaccinations against DTaP diseases. Additionally, with more people preferring to give dosage of these vaccines for their children, followed by growing awareness about these diseases among the population including its causes, remedies and prevention is anticipated to positively drive the growth of the market over the forecast period.
The rise in birth rates and presence of a large geriatric population is anticipated to drive the growth of the market, owing to increased demand for the product by the population belonging to these categories. The vaccines are given to young children and pregnant women to boost their immunity against DTaP disease. Additionally, adults are also given these dosages that can act as a booster in order to help them recover from the effects of lesser vaccine. Moreover, these vaccines are available at lower costs, owing to which their global acceptance and adoption is anticipated that is expected to boost the growth of the market over the forecast period.
The market for DTaP vaccines is anticipated to foresee a steady rate of growth in the underdeveloped nations, owing to the inadequate levels of awareness among the population about DTaP vaccines in these nations. This could encourage more market players to tap the market potential prevailing in these nations for expanding their outreach in these markets, by bringing in more awareness about DTaP vaccines and explaining the benefits of staying vaccinated to protect individuals from any illnesses associated with DTaP.
The side effects associated with vaccine for individuals such as high fever upto 105F, seizures that can affect for a longer period, coma, fussiness and many more are anticipated to hinder the growth of the market over the forecast period. Additionally, in some cases infants are allergic to vaccine medication. Sometimes, proper post vaccine care is not received, that could affect the health of individuals. All these factors are anticipated to act as restraints to the growth of the market over the forecast period.
The high research and development costs connected to development of these vaccines could limit the opportunity for bringing out more innovations and restrict any further medical developments in this field and act as a barrier to the growth of the market over the forecast period.
Our-in depth analysis of the diphtheria, tetanus and pertussis vaccine (DTaP) market includes the following segments:
On the basis of regional analysis, the diphtheria, tetanus and pertussis vaccine (DTaP) market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
The market in North American region is anticipated to hold the leading market share over the forecast period, owing to presence of major market players in the region. The high adoption of these vaccines coupled with high awareness about these diseases are anticipated to increase the growth of the market. Additionally, the increasing private sector investment in research and development of healthcare industry is anticipated to increase the growth of the market over the forecast period. The market in Europe is also anticipated to witness huge growth in the market during forecast period, owing to increase in research & development activities coupled with rise in investments in healthcare sector. The market in Asia-Pacific is expected to witness fastest growth on the account of higher rate of population growth and increased adoption of vaccine. The growing number of government initiatives, for instance the efforts of National Health Mission in India that is working towards addressing the health needs of many areas especially in the rural areas is anticipated to contribute to the growth of the market in the region over the forecast period. The market in Middle East and Africa is estimated to witness slow growth, owing to lesser availability of vaccines and lower levels of awareness about these vaccinations in the region.
The diphtheria, tetanus and pertussis vaccine (DTaP) market is further classified on the basis of region as follows:
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization